In a bold move that reshapes their bullpen, the Yankees have non-tendered five relievers, freeing up valuable roster spots and sparking conversations about the team's future strategy. But here's where it gets controversial: while some of these decisions seem straightforward, others leave fans and analysts scratching their heads. Let’s dive into the details and explore what this means for the Yankees moving forward.
At Friday’s trade deadline, the Yankees announced they would not offer contracts to Mark Leiter Jr., Ian Hamilton, Scott Effross, Jake Cousins, and Michael Arias, effectively making them free agents. This clears five spots on the 40-man roster, giving the team flexibility for the upcoming season. Meanwhile, the Yankees secured one-year deals with Clarke Schmidt and Oswaldo Cabrera, avoiding arbitration with both players.
Mark Leiter Jr., acquired from the Cubs at the 2024 deadline, was a high-strikeout arm with a devastating splitter. However, his time in pinstripes was underwhelming, as he allowed 14 runs in 21.2 innings late in the season. Despite a strong playoff performance, including three scoreless innings in the World Series, his 4.84 ERA in 59 appearances this season sealed his fate. At 35 in March, the Yankees decided to part ways with the veteran, who was projected to earn $3 million in arbitration. But was this the right call? Could his postseason success have warranted another chance?
Ian Hamilton burst onto the scene in 2023 with a 2.64 ERA and an elite 34.6% whiff rate, thanks to his wipeout slider. However, injuries and inconsistency derailed his progress, and he finished this season at Triple-A with a 6.00 ERA in 19 appearances. Even with a projected arbitration salary of just $941,000, the Yankees opted to move on. Is this a case of cutting ties too soon, or was his decline irreversible?
Scott Effross, the longest-tenured Yankee among the non-tendered group, showed promise in 2022 with a 2.84 ERA in 13 appearances. But a UCL injury sidelined him, and he struggled to regain form, allowing 12 runs in 14 innings over the past two seasons. With a projected arbitration salary of $800,000, the Yankees decided it was time to part ways. Was this injury-driven decline too much to overlook?
Jake Cousins was a key bullpen piece in 2024, posting a 2.37 ERA in 38 innings. However, an elbow injury led to Tommy John surgery in June, casting doubt on his 2026 availability. Despite his potential, the Yankees had to let him go, as he was projected to earn $841,000 in arbitration. Could this be a missed opportunity if he returns to form?
Michael Arias, acquired from the Cubs last offseason, never appeared for the Yankees but impressed with a 2.73 ERA across four minor-league levels. At just 24, the pre-arbitration pitcher could have had his contract renewed, but the Yankees lacked a 40-man roster spot. Was this a numbers game, or did the team undervalue his potential?
On a brighter note, the Yankees locked in deals with Clarke Schmidt and Oswaldo Cabrera, avoiding arbitration. Schmidt, who underwent his second Tommy John surgery in July, will earn $4.5 million in 2026, slightly below the projected $4.9 million. Cabrera, expected to be 100% for spring training after recovering from a broken ankle, signed for $1.2 million, matching projections. Is this a smart move to secure key players, or are the Yankees taking a risk with Schmidt’s recovery timeline?
The Yankees still have eight arbitration-eligible players without new deals, including Jazz Chisholm Jr., David Bednar, and Anthony Volpe. With projected salaries ranging from $1 million to $10.2 million, the team faces tough decisions ahead. Which players are worth the investment, and who might be on the chopping block next?
What do you think? Are the Yankees making the right moves to rebuild their bullpen, or are they letting too much talent slip away? Share your thoughts in the comments—let’s spark a debate!
